RecruitingNCT04578171
Residual Exacerbations With Mepolizumab
Type and Mechanisms of Residual Asthma Exacerbations in Patients Treated With Mepolizumab
Sponsor
Laval University
Enrollment
60 participants
Start Date
Jul 6, 2021
Study Type
OBSERVATIONAL
Conditions
Summary
This will be a two-year prospective study to characterize the nature of the remaining asthma exacerbations in patients treated with mepolizumab. Participants will be assessed every six months from pre- until two years of treatment in addition to whenever they experience an exacerbation of asthma during the study period. During these visits, various clinical, physiological and inflammatory outcomes will be assessed.
Eligibility
Min Age: 18 YearsMax Age: 90 Years
Inclusion Criteria3
- With a proven diagnosis of severe asthma as defined by the Canadian Thoracic Society
- Eligible for mepolizumab treatment
- Able and willing to sign the informed consent form
Exclusion Criteria2
- Any respiratory disease apart from asthma
- Confounding comorbidities sur as eosinophilic granulomatosis with polyangiitis (EGPA) or hypereosinophilic syndrome
Interventions
DRUGMepolizumab
100 mg subcutaneous injections every four weeks
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04578171
Related Trials
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma
NCT06664619138 locations
A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations
NCT06052267393 locations
Genetic Association With Various Severities, Phenotypes and Endotypes of Asthma.
NCT061960342 locations
To Assess the Management of Patients on Global Initiative of Asthma (GINA) Step 4 and 5 Treatment in Hong Kong
NCT046397911 location
Relationship of Airway Microbiota, Endotype and Phenotype in Adult Asthma
NCT047069881 location